Is Cara Therapeutics a Buy?
Investors combing the markets for promising growth stocks might have noticed a biotech company called Cara Therapeutics (NASDAQ: CARA). With a market cap of $990 million, Cara Therapeutics enjoyed a strong performance in 2019, with its stock up by almost 50% this year, piquing the interest of many investors.
While the company reported its Q3 earnings a couple of weeks ago, the main driver for Cara Therapeutics' impressive results is the strength of its main drug candidate, which is meant to treat a specific type of skin itching called pruritus, which is caused by chronic kidney disease. With solid clinical trial results to show off, let's take a look at both the company's financials and its results to see whether this biotech stock is worth a spot in your portfolio.
Image source: Getty Images.
Source Fool.com
